33.76
-0.35 (-1.03%)
| Previous Close | 34.11 |
| Open | 34.80 |
| Volume | 908,711 |
| Avg. Volume (3M) | 1,810,937 |
| Market Cap | 2,037,784,704 |
| Price / Sales | 5.03 |
| Price / Book | 3.87 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Profit Margin | -54.98% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -3.25 |
| Quarterly Revenue Growth (YOY) | 23.20% |
| Total Debt/Equity (MRQ) | 18.25% |
| Current Ratio (MRQ) | 4.51 |
| Operating Cash Flow (TTM) | -56.11 M |
| Levered Free Cash Flow (TTM) | -16.89 M |
| Return on Assets (TTM) | -15.04% |
| Return on Equity (TTM) | -38.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Twist Bioscience Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 0.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 1.98% |
| % Held by Institutions | 115.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 42.00 (Evercore ISI Group, 24.41%) | Buy |
| Median | 41.00 (21.45%) | |
| Low | 40.00 (Barclays, 18.48%) | Buy |
| Average | 41.00 (21.45%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 30.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 07 Oct 2025 | 42.00 (24.41%) | Buy | 31.12 |
| Barclays | 02 Oct 2025 | 40.00 (18.48%) | Buy | 30.68 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHO DENNIS | 33.57 | - | 29,518 | 990,919 |
| FINN PATRICK JOHN | 33.57 | 31.83 | 77,545 | 2,607,083 |
| GREEN PAULA | 33.57 | - | 35,513 | 1,192,171 |
| LAPONIS ADAM | 33.57 | - | 25,000 | 839,250 |
| LEPROUST EMILY M. | 33.57 | - | 168,976 | 5,672,524 |
| WERNER ROBERT F. | 33.57 | - | 5,633 | 189,100 |
| Aggregate Net Quantity | 342,185 | |||
| Aggregate Net Value ($) | 11,491,048 | |||
| Aggregate Avg. Buy ($) | 33.57 | |||
| Aggregate Avg. Sell ($) | 31.83 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHO DENNIS | Officer | 28 Oct 2025 | Acquired (+) | 29,518 | 33.57 | 990,919 |
| LAPONIS ADAM | Officer | 28 Oct 2025 | Acquired (+) | 25,000 | 33.57 | 839,250 |
| GREEN PAULA | Officer | 28 Oct 2025 | Acquired (+) | 35,513 | 33.57 | 1,192,171 |
| FINN PATRICK JOHN | Officer | 28 Oct 2025 | Acquired (+) | 79,785 | 33.57 | 2,678,382 |
| LEPROUST EMILY M. | Officer | 28 Oct 2025 | Acquired (+) | 168,976 | 33.57 | 5,672,524 |
| WERNER ROBERT F. | Officer | 28 Oct 2025 | Acquired (+) | 5,633 | 33.57 | 189,100 |
| FINN PATRICK JOHN | Officer | 23 Oct 2025 | Sell (-) | 2,240 | 31.83 | 71,299 |
| Date | Type | Details |
|---|---|---|
| 23 Oct 2025 | Announcement | Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025 |
| 06 Oct 2025 | Announcement | Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System |
| 02 Oct 2025 | Announcement | Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design |
| 03 Sep 2025 | Announcement | Twist Bioscience to Present at Baird 2025 Global Healthcare Conference |
| 02 Sep 2025 | Announcement | Twist Bioscience Collaborates with Synthetic Design Lab |
| 19 Aug 2025 | Announcement | Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution |
| 06 Aug 2025 | Announcement | Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors |
| 04 Aug 2025 | Announcement | Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |